Avalo Therapeutics, Inc. (AVTX) Financials

AVTX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 490.8 million 42.1 million
March 31, 2026 99.9 million 31.6 million
Dec. 31, 2025 116.5 million 33.4 million
Sept. 30, 2025 125.1 million 33.6 million

AVTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -18.1 million 5.3 million
March 31, 2026 -17.7 million 3.6 million
Dec. 31, 2025 -14.2 million 4.5 million
Sept. 30, 2025 -16.4 million 3.2 million

AVTX Net Income

No data available :(

AVTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 400.3 million - 242000
March 31, 2026 82.0 million 2.0 million 328000
Dec. 31, 2025 98.3 million 2.0 million 427000
Sept. 30, 2025 111.6 million - 555000

AVTX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 43.6 million
March 31, 2026 20.1 million
Dec. 31, 2025 18.5 million
Sept. 30, 2025 14.0 million

AVTX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 23.4 million 8.1 million 126000
March 31, 2026 - 14.0 million 6.8 million -
Dec. 31, 2025 - 13.3 million 6.5 million 381000
Sept. 30, 2025 - 13.6 million 5.6 million 22000

AVTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 17000
Dec. 31, 2025 59000 16000
Sept. 30, 2025 - 10.0 million

AVTX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

AVTX

Price: $19.59

52 week price:
7.87
24.27

Earnings Per Share: -4.41 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 45800

Market Capitalization: 1.0 billion

Links: